ClinicalTrials.Veeva

Menu

Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status and phase

Completed
Phase 3

Conditions

Haemophilus Influenzae Type B
Hepatitis B

Treatments

Biological: Comparator: COMVAX™
Biological: Comparator: Modified Process Vaccine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00441012
V121-019
2007_513

Details and patient eligibility

About

To determine if there is an improvement in the immune response to HBsAg (hepatitis B virus) in healthy infants using a modified process in a combination Haemophilus Influenzae, type b/Hepatitis B vaccine and a currently licensed Haemophilus Influenzae, type b/Hepatitis B vaccine

Enrollment

546 patients

Sex

All

Ages

40 to 80 days old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy 2-month-old full term infants born to non-HBs Ag (hepatitis B virus) carrier mothers

Exclusion criteria

  • Birth mother known to be a carrier of hepatitis B virus (HBsAg+) or known carriers ever living in close contact with the subject
  • History of previous hepatitis B infection; history of vaccination with any hepatitis B vaccine
  • Recent (<72 hours) history of febrile illness (rectal temperature >=38.1°C/>=100.5°F)
  • Known or suspected hypersensitivity to any component of RECOMBIVAXHB™ or COMVAX™ (e.g., aluminum, yeast)
  • Recent administration (w/i 3 months prior to study start) of hepatitis B immune globulin (HBIg), serum immune globulin, or any other blood-derived product
  • Receipt of investigational drugs or investigational vaccines within 3 months prior to study start or if planned within the study period;
  • Known or suspected impairment of immunologic function or recent use (within 3 months prior to study start) of immunomodulatory medications (does not include topical and inhaled steroids);
  • Any condition that, in the opinion of the investigator, might interfere with the evaluation of study objectives; or inability to comply with the study schedule and/or inability to attend all required study visits

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

546 participants in 2 patient groups

1
Experimental group
Description:
Modified process Hib/Hep B vaccine
Treatment:
Biological: Comparator: Modified Process Vaccine
2
Active Comparator group
Description:
COMVAX™
Treatment:
Biological: Comparator: COMVAX™

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems